Two RV Component Giants Are Merging to Build an $8.1 Billion Outdoor Powerhouse

Two of the most important names in the recreational vehicle and outdoor recreation supply chain are joining forces. Patrick Industries (Nasdaq: PATK) and LCI Industries (NYSE: LCII) the latter known commercially as Lippert announced Tuesday they have entered into a definitive agreement to combine in an all-stock merger, creating a premier component solutions provider serving the outdoor enthusiast, housing, and transportation markets. The boards of both companies unanimously approved the transaction.

Under the terms, LCI shareholders will receive 1.2440 shares of Patrick common stock for each LCI share they own. When the deal closes, Patrick shareholders will own approximately 52% of the combined company and LCI shareholders approximately 48% — a near-even split that reflects the comparable scale of the two businesses.

The Scale of the Combined Company

The merger creates a genuine industry heavyweight. On a pro forma basis, the combined company would have generated approximately $8.1 billion in revenue over the trailing twelve months as of March 2026, with adjusted EBITDA of $1.0 billion and free cash flow of $508 million, both inclusive of expected synergies. Those are substantial figures in the component manufacturing space and give the combined entity meaningful scale across its end markets.

The financial case rests heavily on cost synergies. Management expects the transaction to deliver more than $150 million in run-rate cost savings within three years of closing. The company describes those synergies as identified and actionable, arising primarily from procurement efficiencies, selling, general and administrative streamlining, shared engineering best practices, and improved supply chain management, the kind of operational overlap that two companies serving similar customers and end markets can realistically capture.

Why These Two Companies Fit Together

Both Patrick and LCI are component solutions providers with deep, longstanding relationships across the recreational vehicle, marine, manufactured housing, and broader outdoor recreation industries. They supply the parts and systems that go into RVs, boats, manufactured homes, and other products built for life outdoors. Their portfolios are complementary rather than overlapping in a way that would raise significant antitrust concern, and both maintain established customer partnerships across North America and Europe.

The combined leadership structure reflects the partnership nature of the deal. Patrick’s Andy Nemeth will serve as CEO of the combined company, while Todd Cleveland will become Chair and LCI’s Johnny Sirpilla will serve as Vice Chair of the board. That distribution of senior roles across both legacy organizations signals an intent to integrate the two cultures rather than have one absorb the other.

The Cyclical Context

The timing of this combination is worth understanding. The recreational vehicle and outdoor recreation industries are highly cyclical, and they have navigated a challenging stretch as elevated interest rates pressured big-ticket discretionary purchases like RVs and boats throughout 2025 and into 2026. By combining, Patrick and LCI gain the scale, cost structure, and balance sheet flexibility to weather cyclical downturns more effectively and to invest through the cycle rather than retrench during it.

For investors tracking the small and mid cap industrial and consumer discretionary space, this merger carries a familiar signal. In sectors facing cyclical pressure and margin compression, scale becomes a defensive advantage. Companies with complementary products and overlapping cost structures are increasingly choosing to combine rather than compete, pooling resources to improve procurement leverage, operational efficiency, and resilience. The outdoor recreation supply chain just produced one of the clearest examples of that logic in 2026 at $8.1 billion in combined revenue, the resulting company will be a dominant force in its markets when conditions in the RV and outdoor industries eventually turn back up.

Star Equity Holdings, Inc. (STRR) – A First Step


Tuesday, June 30, 2026

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Russell Microcap Index.  Star Equity Holdings’ common stock has been added to the Russell Microcap® Index following the 2026 Russell indexes reconstitution, which became effective after the U.S. market close on June 26, 2026. We view the inclusion of Star in the Microcap Index as the first step in management’s goal to be added to the Russell 2000 Index.

Russell Microcap Index. The reconstitution of the Russell U.S. Indexes captures the 4,000 largest U.S. stocks as of April 30, 2026, ranked by total market capitalization. The Russell Microcap® Index measures the performance of the microcap segment of the U.S. equity market and is used by institutional investors and investment managers as a benchmark for microcap equities.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

NN (NNBR) – Expanding Data Center Business


Tuesday, June 30, 2026

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

New Awards. NN has secured a significant amount of additional 2026 immediate-supply awards for liquid cooling products that go into NVIDIA AI data center racks. The new awards are additive to prior communicated awards and greatly increase the size of NN’s liquid cooling product portfolio for AI data center racks. NN’s combined Data Center and Electric Grid business is already its 2nd-largest business, with a goal to grow it into the Company’s largest business by sales. The Data Center & Electric Grid end markets are the top targeted growth markets for the Company.

Successful Launch. In 1Q26, NN announced the launch of a custom-designed stainless-steel product line for the liquid-cooled data center market. Since then, the Company has secured multiple AI data center awards, invested in an initial complement of 17 next-generation, high-speed, high-precision CNC machines at its Wuxi, China, plant, and begun production.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Why Small-Cap Companies Have Become the Most Coveted Acquisition Targets of 2026

The deal winter is over. After years of stalled negotiations and a near-frozen M&A market, 2026 has arrived with a thaw that is reshaping the opportunity landscape for investors at every level. U.S. merger and acquisition transactions over $100 million are up 25% by volume and 43% by value compared to the same period last year, and the companies drawing the most aggressive attention are not the household names. They are the smaller, leaner innovators that large strategics and private equity firms have been quietly circling.

The catalyst is a convergence of factors that rarely align at once. Nearly $440 billion in private equity dry powder is specifically earmarked for smaller enterprises. Stabilizing interest rates following years of Fed tightening have narrowed the valuation gap that froze so many deals. And a shift in antitrust enforcement, with the FTC under new leadership focusing scrutiny on mega-mergers rather than smaller bolt-on acquisitions, has cleared a regulatory runway that simply did not exist two years ago.

Biopharma Is Driving the Biggest Wave

Nowhere is the acquisition appetite more pronounced than in life sciences. IQVIA forecasts aggregate biopharma M&A deal value of $140 billion to $160 billion for full-year 2026, with upside potential of an additional $20 to $30 billion. Oncology is the primary target area, accounting for roughly 39% of total transaction volume. Large pharmaceutical companies facing patent cliffs on blockbuster drugs are finding it more capital-efficient to acquire late-stage small-cap biotechs than to fund the same pipeline development in-house.

Small-cap developers in oncology, rare disease, and high-growth therapeutic categories like GLP-1 drugs, where the market opportunity is projected to reach $100 billion by 2030, are drawing the most serious acquirer interest. Companies like Cardiff Oncology and MAIA Biotechnology are among the smaller-cap names building programs in therapeutic areas where large-cap acquirers are actively hunting for pipeline replenishment.

How Deal Structures Have Evolved

It is not just volume that has shifted. The mechanics of how deals get done have evolved as well. Today’s acquirers are structuring transactions around free cash flow multiples and sustainable margins, rather than the growth-at-any-cost narratives that defined the SPAC era. Contingent value rights (CVRs) are increasingly common, allowing buyers and sellers to share risk on clinical or commercial milestones, which makes smaller biotech deals executable even under significant uncertainty.

This shift favors companies with differentiated science and disciplined financials over those with only a compelling story. For acquirers, the logic is clear: buying validated late-stage assets is cheaper than building them internally, particularly in a higher-rate environment.

What This Means for Small and Microcap Investors

For investors focused on small and microcap companies, this is among the most favorable M&A backdrops in recent memory. Acquisition premiums in small-cap biotech and specialty pharma deals have historically ranged from 50% to over 100% above pre-announcement prices. The profiles that attract strategic buyers, differentiated pipelines, clean balance sheets, and validated mechanisms of action, are concentrated precisely in the sub-$2 billion market cap space where most individual investors are underexposed.

The opportunity is not in chasing deal rumors. It is in understanding the strategic logic driving large-cap acquirers: they need what smaller companies have built, and in 2026, they are increasingly willing to pay for it.

Russell Reconstitution 2026 Takes Effect: 237 New Names Join the Small Cap Index

The Russell US Indexes reconstitution that we previewed earlier this month officially took effect at the close of trading Friday, and US markets opened this morning, Monday June 29, with the newly recalibrated indexes in operation. The timing is notable. Just last week we wrote about the market rotation finally broadening beyond a handful of mega cap technology names and into small caps — and this reconstitution is the structural machinery that formalizes exactly that shift, recalibrating which companies sit in which index after a year of dramatic movement across the market cap spectrum.

After a query period, a lock-down phase, and one of the highest-volume trading sessions of the year on Friday, the 2026 reconstitution is now complete — and the changes offer a revealing snapshot of how the US equity market has evolved over the past twelve months.

A Market That Grew 29% in a Year

The headline figure is the scale of the market’s expansion. The total market capitalization of the Russell 3000 — the broad index designed to capture roughly 98% of the investable US equity market — rose 29% from $58.4 trillion at last year’s reconstitution to $75.6 trillion as of the April 30 rank day. That growth rippled through every layer of the index family. The market capitalization breakpoint separating large-cap companies in the Russell 1000 from small-cap companies in the Russell 2000 increased 24% to $5.7 billion. At the lower boundary, the smallest company in the Russell 2000 now carries a market cap of approximately $146 million, up nearly 23% from a year ago.

A Historic Shakeup at the Top

One of the most striking changes occurred among the largest companies in the index. For more than a decade, Apple and Microsoft traded places as the two largest US companies. This year broke that pattern. Driven by the artificial intelligence boom, Nvidia rose from third place in 2025 to become the largest company in both the Russell 3000 and Russell 1000, while Alphabet climbed from fifth to second. Apple and Microsoft slipped to third and fourth. It is the clearest index-level evidence yet of how completely AI has reshaped market leadership.

The Small Cap Story Beneath the Surface

For ChannelChek’s audience, the more relevant action is happening lower down the market cap spectrum. A total of 237 companies were added to the Russell 2000 this cycle, with additions concentrated most heavily in health care, followed by technology, industrials, and consumer discretionary. That cohort includes 82 companies migrating up from the Russell Microcap Index, 37 moving down from the Russell 1000, and 101 newly eligible entrants joining from outside the Russell universe. Seventeen IPOs were added directly to the small cap index, led by eight health care names.

The reconstitution also revealed the strength of the recent small cap surge through its banding mechanism. A remarkable 97 existing Russell 2000 constituents ranked above the large cap breakpoint based on market cap but remained in the small cap index because they fell within the retention band — a buffer designed to reduce unnecessary turnover. That is an unusually high number, and it reflects just how many small cap companies have appreciated toward large cap territory over the past year.

Why the Semi-Annual Shift Matters Going Forward

This reconstitution carries lasting structural significance because 2026 marks the first time since 1989 that FTSE Russell has moved to a semi-annual schedule. A second reconstitution will now occur in December, and the implications are real. With roughly $12 trillion in assets benchmarked to Russell indexes, the addition of a December rebalance means that companies growing rapidly into or shrinking out of an index will be repositioned far faster than the prior annual cadence allowed.

For active small cap managers, that change raises the stakes around benchmark awareness and risk management. Stocks that appreciate quickly can now be migrated to a new index in months rather than waiting a full year, compressing the window in which fundamental changes get reflected in index composition. For investors, the practical takeaway is that index inclusion remains a powerful driver of passive fund flows and liquidity — but inclusion is not the same as fundamental validation. A company can join an index and still carry execution, dilution, or earnings risk. The reconstitution list is best understood as a map of where benchmark-driven attention may flow, not a substitute for due diligence.

The rebalanced indexes are live. The market they represent looks materially different than it did a year ago — larger at the top, broader beneath the surface, and now recalibrated twice as often as it was for the prior 37 years.

Zymeworks Moves to Acquire Theravance Biopharma in $929 Million Deal

Vancouver-based Zymeworks (Nasdaq: ZYME) announced this morning it has signed a definitive agreement to acquire Theravance Biopharma (Nasdaq: TBPH) for $17.00 per share in cash, a deal valued at roughly $929 million. The transaction adds YUPELRI® (revefenacin), the only nebulized once-daily LAMA approved for COPD maintenance therapy, to Zymeworks’ growing portfolio of partnered commercial assets.

The move is consistent with the strategy Zymeworks outlined earlier this year: pair royalty-generating assets with its internal R&D pipeline to create a more durable, self-funded business. The company has been building toward this kind of deal since pivoting away from a pure drug development model, and today’s announcement is the clearest sign yet that the strategy is gaining traction.

YUPELRI® has been on the U.S. market since 2019, co-promoted by Viatris and Theravance Biopharma. Full-year 2025 net sales came in at $266.6 million, up 12% over the prior year, with Q1 2026 sales of $62.4 million representing 7% growth year-over-year. Zymeworks will receive a 35% U.S. net profit share, which at current run-rates translates to roughly $60 million in annualized cash flow. Generic entry has been pushed to April 2039 following settlements with all filers, giving the asset a clear commercial runway.

Financing the deal involved some creativity. Zymeworks secured a $350 million non-recourse note from OMERS Life Sciences, structured so that 75% of the YUPELRI® profit-share cash flows service the debt. Critically, the note has no recourse to the rest of Zymeworks’ balance sheet. The company will contribute $219 million in existing cash, with Theravance Biopharma’s expected net cash balance of approximately $360 million at closing covering most of the remainder. A $100 million milestone payment from Royalty Pharma related to TRELEGY ELLIPTA® sales is expected in Q1 2027, which effectively cuts Zymeworks’ net cash outlay roughly in half.

Beyond YUPELRI®, the deal brings additional upside. Theravance Biopharma holds royalty interests on VIBATIV® through Cumberland, is eligible for up to $125 million in future YUPELRI® commercial milestones from Viatris, and carries approximately $2.5 billion in Irish tax attributes that Zymeworks intends to preserve for future use. A preclinical inflammation and immunology portfolio also transfers, though Zymeworks has signaled it will evaluate those assets against its broader pipeline priorities.

CEO Kenneth Galbraith framed the deal as core to the company’s longer-term vision of blending commercial cash flows with internal innovation, describing it as a way to fund next-generation therapies while supporting patients who need access today. The boards of both companies have unanimously approved the transaction.

Closing is expected in the second half of 2026, subject to Theravance Biopharma shareholder approval and regulatory clearance. Kirkland & Ellis is serving as legal counsel to Zymeworks, with TD Cowen advising on the OMERS note. Lazard and Evercore are advising Theravance Biopharma.

V2X (VVX) – A Major Recompete Win


Monday, June 29, 2026

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Award. In its daily contract awards, on Friday, the Department of War announced it has awarded V2X subsidiary Vertex Aerospace a $500 million maximum firm-fixed-price, indefinite-delivery/indefinite-quantity contract for contractor logistic support services for the Air Force C-12 aircraft fleet. This is another in a long line of significant awards won by V2X, either new or re-competes, and highlights the Company’s diverse capabilities, in our view.

Details.  This contract provides time-sensitive movement of personnel, cargo, and medical evacuation, as well as test support for Air Force Materiel Command, Defense Intelligence Agency, Defense Security Cooperation Agency, and Pacific Air Forces. The contract is expected to be completed by June 30, 2031. The contract involves Foreign Military Sales. This contract was a competitive acquisition, and three offers were received.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

T3 Defense (DFNS) – Operating at the Critical Chokepoints of the Defense Industrial Base


Monday, June 29, 2026

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Initiation. We are initiating research coverage of T3 Defense Inc. (NASDAQ: DFNS) with an Outperform rating and a $0.80 price target. T3 Defense is a global aerospace & defense holding company focused on acquiring and operating mission-critical defense businesses embedded at critical chokepoints of long-cycle national security programs. Through disciplined M&A, centralized capital and strategy, and decentralized operating autonomy, T3 Defense seeks to build the asymmetric edge by strengthening critical defense capabilities and compound long-term value.

Focus. The strategy targets Tier 2 and Tier 3 suppliers that form the industrial backbone of national security infrastructure, with particular emphasis on companies offering dual-use technologies, advanced AI applications, and critical manufacturing capabilities. Management is targeting high-growth areas in the defense industry, which is undergoing a strategic recapitalization driven by ongoing conflicts and rapid technological change.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

AZZ (AZZ) – AZZ to Report First Quarter FY 2027 Results on July 8; Quarterly Cash Dividend Increased 20%


Monday, June 29, 2026

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Quarterly Dividend Increased. AZZ recently announced a 20.0% increase in its quarterly cash dividend to $0.24 per share, or $0.96 per share on an annualized basis, up from $0.20 per share, or $0.80 per share on an annualized basis, reflecting continued confidence in the company’s financial position and commitment to returning capital to shareholders. The dividend will be paid on July 30 to shareholders of record as of July 9.

First Quarter FY 2027 Financial Results. AZZ will report its first quarter fiscal 2027 financial results after the market closes on July 8, followed by a webcast and conference call on July 9 at 11:00 am ET. In addition to the first-quarter FY 2027 operating performance, we expect management to discuss demand trends, capital allocation priorities, and the outlook for the fiscal year, including potential acquisitions.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

DLH Holdings (DLHC) – Navy Contract


Monday, June 29, 2026

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

New Award. DLH has been awarded a multiple-award indefinite delivery/indefinite quantity (MAC ID/IQ) contract to provide a full range of logistics information technology services for U.S. Navy integrated platforms and DevSecOps pipelines. Under the contract, DLH will implement mission-driven, interoperable, and cost-effective solutions for customers as they confront critical system integration challenges. This new award should enable DLH to expand its offerings to the Navy, opening a new growth channel for the Company.

Details. DLH is one of multiple prime awardees on the contract, which includes a 5-year base period. The contract has a $250 million ceiling for all awardees. Task orders are expected to be released under the contract, for which DLH expects to compete.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

The Rotation Investors Have Waited All Year For Is Finally Happening

For most of 2026, the case for a market broadening beyond a handful of mega cap technology names has been a thesis. As of this week, it is becoming a reality. A global technology selloff intensified Friday, dragging the Nasdaq toward its fourth consecutive session of losses, while the parts of the market that had been overlooked for months quietly moved in the opposite direction. The Dow Jones Industrial Average touched a fresh all-time intraday high this week. And the Russell 2000, the benchmark for small cap stocks, pushed toward the 3,000 level after months of underperformance.

This is the rotation. And the data underneath it suggests it may have staying power.

What’s Driving the Move

The catalyst on the surface is weakness in technology. Apple and Microsoft both fell after announcing price increases on consumer hardware tied to rising memory costs, a reported delay in OpenAI’s IPO rattled sentiment around AI valuations, and a sharp selloff in Asian tech markets — South Korea’s KOSPI triggered a circuit breaker after an 8% intraday drop — spilled into US trading. Investors are reassessing whether the largest technology companies can justify the valuations the market assigned them during the AI rally.

But the more important story is where the money is going, not just what it’s leaving. Underneath the tech weakness, market breadth is expanding meaningfully. By late Thursday, 63% of S&P 500 stocks were trading above their 50-day moving average, up from 50% at the start of June. Advancing stocks have consistently outnumbered decliners even on down days for the index. And the correlation between the cap-weighted and equal-weighted versions of the S&P 500 has fallen to its lowest level since 2003 — a technical signal that the market is no longer moving in lockstep with a few giant names.

The Tailwinds Beneath Small Caps

Several forces are converging to support the move into smaller, more domestically focused companies. The 10-year Treasury yield has dropped below 4.5% as oil prices retreat on the easing Iran conflict, lowering borrowing costs for the smaller companies that carry disproportionately more variable-rate debt. The Russell 2000 has surged roughly 21% in 2026 while the S&P 500 has added less than 10%, and the valuation gap between the two remains near its widest level in over two decades.

The breadth of the rally is visible across exactly the kinds of sectors that had been left behind. Industrials and domestic manufacturers — names ranging from blue-chip Caterpillar down to smaller players like FreightCar America and Titan International — sit directly in the path of the onshoring and infrastructure investment themes driving the broadening. Consumer-facing companies such as ONE Group Hospitality and energy producers including Alliance Resource Partners operate in corners of the market that benefit when capital rotates away from crowded technology positioning and toward businesses with tangible cash flows and reasonable multiples.

What Comes Next

The question now is durability. If Treasury yields continue declining and oil stays contained, the conditions supporting the rotation strengthen. If tech stabilizes and reclaims leadership, the broadening could stall as it did in March and April. But the structural case for small caps — historic valuation discounts, improving earnings growth, and domestic revenue exposure — has been intact all year. What changed this week is that the market finally started pricing it in. For investors who positioned early, the rotation they have been waiting for is no longer a forecast. It is happening in real time.

Newsmax (NMAX) – Recurring Revenue Mix Improves; EBITDA Outlook Strengthens


Friday, June 26, 2026

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Jacob Mutchler, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Strong operating momentum despite a challenging comparison. First-quarter revenue growth was driven by affiliate fee expansion, licensing growth, and improved distribution economics, while Newsmax maintained strong audience engagement with 30.4 million viewers and posted a 29% sequential increase in total viewership versus Q4 2025.

Meaningfully improving earnings outlook. We are raising our 2026 adjusted EBITDA estimate to a loss of $3.4 million, up from our prior estimate of $16.4 million. While our revenue outlook remains largely unchanged, the improved profitability reflects a more favorable revenue mix, lower operating expense assumptions, and increasing confidence in management’s execution.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Commercial Vehicle Group (CVGI) – To Join Russell 2000; $25M ATM


Friday, June 26, 2026

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Russell 2000. Commercial Vehicle Group (CVG) is expected to join the U.S. small-cap Russell 2000 Index and the broad-market Russell 3000 Index as part of the 2026 reconstitution of the Russell U.S. Indexes. The reconstituted indexes will take effect after the U.S. equity markets close on Friday, June 26, 2026. We expect the potential for additional demand for CVGI shares as index funds recalibrate portfolios to adjust for index newcomers.

Sales Agreement. Late last week, CFG entered into a “Capital on Demand” sales agreement for the sale of up to $25 million of CVGI shares. At the then $5.29 share price at the time of the filing, the full $25 million represented approximately 4.7 million shares, which would increase shares outstanding by 11.5%.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.